Clinical Trial Update: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A National Cancer Institute trial is evaluating the combination of mirdametinib and sirolimus in relapsed/refractory, RAS-mutated multiple myeloma (Phase 1/2), …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Mirdametinib (mirdametinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1, Phase 2 | Status: SUSPENDED